THE EFFECT OF STATIN USE ON VASCULAR FUNCTION IN HYPERTENSIVE SUBJECTS

他汀类药物的使用对高血压患者血管功能的影响

• 批准号: 7375818
• 负责人: PAMELA OUYANG
• 金额: $ 1.23万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7375818
• 关键词: EFFECT; STATIN; USE; VASCULAR; FUNCTION

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Hypertension, a common risk factor for atherosclerosis, occurs without a known or reversible cause in over 90% of cases, and adjunct strategies are needed to reduce its complications, such as vascular dysfunction. Clinical trials have shown that HMG-CoA reductase inhibitor (statin) therapy reduces cardiovascular mortality and morbidity. This benefit is seen in patients with and without high blood cholesterol levels. Non-lipid actions of statins including effects on the blood vessel wall, the microvasculature and systemic inflammation are likely to be responsible for this benefit. The purpose of this study is to more fully investigate the effects of statins on endothelial dysfunction (both conduit and microvascular), arterial stiffness, inflammation and impaired nitric oxide metabolism, which are potential pathophysiologic mechanisms leading to increased cardiovascular risk in hypertensive individuals.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。高血压是动脉粥样硬化的常见危险因素，超过 90% 的病例发生原因不明或可逆，因此需要采取辅助策略来减少其并发症，例如血管功能障碍。临床试验表明，HMG-CoA 还原酶抑制剂（他汀类药物）治疗可降低心血管死亡率和发病率。无论患有或不患有高血液胆固醇水平的患者都可以看到这种益处。他汀类药物的非脂质作用，包括对血管壁、微脉管系统和全身炎症的影响，可能是造成这种益处的原因。本研究的目的是更全面地研究他汀类药物对内皮功能障碍（导管和微血管）、动脉僵硬度、炎症和一氧化氮代谢受损的影响，这些是导致高血压个体心血管风险增加的潜在病理生理机制。